In separate obesity trials, tirzepatide 15mg achieved 20.9% body weight reduction (SURMOUNT-1) compared to semaglutide 2.4mg's 14.9% (STEP 1)
The FDA specifically stated that our preliminary evaluation has not found evidence that use of these medicines causes suicidal thoughts or actions while the MHRA noted that the available evidence does not establish a causal relationship between GLP-1 receptor agonists and suicidal behavior, suicidal ideation, self-injury and depression. Taken together, these formal investigations did not reveal evidence of a causal relationship between the use of GLP-1s and suicidal thoughts, self-injurious behavior, or even depression
Peralta-Reich, a double-board certified obesity medicine and pediatrics doctor
Retatrutide is currently undergoing large-scale Phase 3 clinical trials (the TRIUMPH program)
Online care can be a good starting point for straightforward casesyour clinician reviews symptoms, history, allergies, and current medications before deciding whether treatment is appropriate